Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Vriesendorp, Huibert M ^a,d   Quadri, Syed M ^b   Wyllie, Cynthia T ^c   Lai, Jing ^a   Borchardt, Paul E ^a   Harris, Leigh ^a   Wucher, Robin ^a   Askew, Eileen ^a   Schweichler, Louis ^a  

^a Arlington Cancer Center   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; FERRITIN ANTIBODY; INDIUM 111; YTTRIUM 90;

ADOLESCENT; ADULT; AGED; BLOOD TOXICITY; CHILD; CONFERENCE PAPER; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; DOSE FRACTIONATION; FEMALE; FERRITINS; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; QUALITY CONTROL; RABBITS; RADIOIMMUNOTHERAPY; RECURRENCE;

EID: 0032723746     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Eshbar, Z., Order, S. E., and Katz, D. H. Ferritin, a Hodgkin's disease-associated antigen. Proc. Natl. Acad. Sci. USA, 71: 3956-3960, 1974.
2. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L., Leichner, P. K., Loudenslager, D. M. and Order, S. E. Phase I-II studies of yttrium-90 labeled antiferritin treatment for end-stage Hodgkin's disease, including RTOG 87-01. J. Clin. Oncol., 9: 918-928, 1991.
3. Vriesendorp, H. M., Quadri, S. M., Wyllie, C. T., Andersson, B. S., and Dicke, K. A. Therapeutic ratio of yttrium-90 labeled antiferritin therapy for recurrent Hodgkin's disease. In: K. A. Dicke and A. Keating (eds.), Autologous Marrow and Blood Transplantation: Proceedings of the Eighth International Symposium, pp. 625-638. Charlottesville, VA: Carden Jennings Co., 1997.
4. Herbst, J. M., Klein, J. L., Leichner, P. K., Quadri, S. M., and Vriesendorp, H. M. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium-90 labeled antiferritin treatment. J. Clin. Oncol., 13: 2394-2400, 1995.
5. Vriesendorp, H. M., Morton, J. D., and Quadri, S. M. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res., 55 (Suppl.): 5888s-5892s, 1995.
6. Borchardt, P. E. Radiolabeled human monoclonal IgM for intracompartmental cancer therapy (Thesis). Houston, TX: University of Texas, 1997.
7. Schlom, J., Molinolo, A., and Simpson, J. F. Advantages of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst., 141: 292-302, 1990.
8. Vriesendorp, H. M., Shao, Y., Blum, J. E., Quadri, S. M., and Williams, J. R. Fractionated intravenous administration of Y-90 labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl. Med. Biol., 20: 571-578, 1993.
9. Lai, J., Quadri, S. M., Borchardt, P. E., Harris, L., Wucher, R., Askew, E. Schweichler, L., and Vriesendorp, H. M. Pharmacokinetics of radiolabeled antiferritin in Hodgkin's disease. Clin. Cancer Res., 5 (Suppl.): 3315s-3323s, 1999.
10. Vriesendorp, H. M., Quadri, S. M., Stinson, R. L., Onyekwere, O. C., Shao, Y., Klein, J. L., Leichner, P. K., and Williams, J. R. Selection of reagents for human radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 22: 37-45, 1992.
11. Schneider, S., and McGuire, S. A. (eds.). NUREG-1492: Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material, Final Report. Washington, DC: Division of Regulatory Applications, Office of Nuclear Regulatory Research, United States Nuclear Regulatory Commission, 1997.
12. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., and Dicke, K. A. Hematological side effects of radiolabeled immunoglobulin therapy. Exp. Hematol., 24: 1183-1190, 1996.
13. Vriesendorp, H. M. Influence of radiation dose and radiation field size on the induction or treatment of leukemia. Semin. Hematol., 28: 25-31, 1991.
14. Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., and Rosenberg, S. A. Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med., 318: 76-81, 1988.
15. Hubscher, S. G., Lumley, M. A., and Elias, E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology, 17: 70-77, 1993.
16. Cohen, P. R., and Kurzrock, R. Sweet's syndrome and malignancy. Am. J. Med., 82: 1220-1226, 1987.
17. Lokich, J. J., Galvanek, E. G., and Moloney, W. C. Nephrosis of Hodgkin's disease. Arch. Intern. Med., 132: 597-600, 1973.
18. Kaplan, H. S. Hodgkin's Disease, 2nd ed. London: Harvard University Press, 1980.
19. Knox, S. J., Goris, L., Trisler, K., et al. Yttrium-90 labeled anti-CD20 monoclonal antibody. Therapy of recurrent B-cell lymphoma. Clin. Cancer Res., 2: 457-470, 1996.
20. Vriesendorp, H. M., Quadri, S. M., and Borchardt, P. E. Tumour therapy with radiolabelled antibodies: optimisation of therapy. Biodrugs, 4: 275-293, 1998.
21. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., Wyllie, C. T., and Dicke, K. A. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration. Cancer (Phila.), 80: 2721-2727, 1997.
22. Klein, J. L., Nguyen, , Laroque, P., Kopher, K. A., Williams, J. R., Wessels, B., Dillehey, L. E., Frincke, J., Order, S. E., and Leichner, P. K. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental hepatoma. Cancer Res., 46: 63-83, 1989.